MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
1.040
+0.030
+2.97%
Pre Market: 1.060 +0.02 +1.91% 08:39 04/07 EDT
OPEN
0.9999
PREV CLOSE
1.010
HIGH
1.140
LOW
0.9999
VOLUME
148
TURNOVER
0
52 WEEK HIGH
2.380
52 WEEK LOW
0.5301
MARKET CAP
50.54M
P/E (TTM)
-0.8004
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HOWL last week (0330-0403)?
Weekly Report · 1d ago
Weekly Report: what happened at HOWL last week (0323-0327)?
Weekly Report · 03/30 09:50
Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price
TipRanks · 03/28 06:05
Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation
TipRanks · 03/27 11:16
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)
TipRanks · 03/27 11:15
Earnings Scheduled For March 27, 2026
Benzinga · 03/27 11:11
Werewolf Therapeutics to explore range of strategic alternatives
TipRanks · 03/27 11:10
Werewolf Therapeutics Q4 net loss narrows as expenses fall
Reuters · 03/27 11:10
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.